LUIS BENALCAZAR: Open Payments
NPI 1801878269 · ELIZABETH, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$702 in 40 payments from 15 companies in 2025. Trend: 2023 $1,905 · 2024 $868 · 2025 $702
Food & beverage: $702
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $206 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $139 |
| Abbott Laboratories | 4 | $57 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $54 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
| Amgen Inc. | 2 | $31 |
| Novo Nordisk Inc | 2 | $29 |
| Dexcom, Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
Products named: JARDIANCE, FARXIGA, FREESTYLE LIBRE 3, XIFAXAN, BREZTRI, ZENPEP, OTEZLA, Dexcom G6 Transmitter.
Industry payments across NJ — which companies pay providers there.
